FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.

Real-world evidence shows advanced Crohn’s therapies have similar risks for serious infections, VTE, and cardiovascular events, supporting treatment decisions based primarily on effectiveness.

Research shows stroke survivors who suppress emotions face poorer physical and cognitive recovery, highlighting need for routine mental health screening, open communication, and integrated emotional support.

The American Academy of Sleep Medicine released first inpatient obstructive sleep apnea guidelines, promoting hospital screening, continued PAP therapy, specialist consultation, and structured discharge planning.

Financial incentives, including medication discounts, may improve adherence and outcomes for low-income adults with poorly controlled type 2 diabetes, reducing complications and healthcare costs.

New research suggests certain antiplatelet medications may worsen outcomes after brain bleeds, prompting clinicians to reassess prescribing decisions and emergency management strategies.

Rising numbers of elderly Americans with mitral regurgitation are driving personalized treatment strategies, balancing surgery and minimally invasive options to improve outcomes and quality of life.

New Alzheimer’s research identifies molecularly distinct patient subgroups, paving the way for personalized treatments tailored to biological profiles, lifestyles, and individual care needs.

Biological aging metrics may transform steatotic liver disease care, enabling better risk assessment, earlier interventions, and more personalized treatment strategies beyond chronological age alone.

New insights suggest starting hormone therapy after age 65 may raise cancer and heart risks, prompting personalized discussions about timing, benefits, and safer menopause management.